Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2012 by AZ Jan Palfijn Gent.
Recruitment status was  Recruiting
Onze Lieve Vrouw Hospital
Information provided by (Responsible Party):
Dr. Decleer Wim, AZ Jan Palfijn Gent Identifier:
First received: May 4, 2012
Last updated: May 24, 2012
Last verified: May 2012

The purpose of this study is to see whether patients triggered with only hCG have higher number of M2-oocytes and implantation rate than patients triggered with hCG combined with GnRH agonist.

Condition Intervention Phase
Drug: Decapeptyl / Gonapeptyl Daily
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomised Controlled Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist

Resource links provided by NLM:

Further study details as provided by AZ Jan Palfijn Gent:

Primary Outcome Measures:
  • M2 oocytes [ Time Frame: patients will be followed during the stimulation with an average of 10 days ] [ Designated as safety issue: No ]
    the number of mature oocytes retrieved after stimulation without creating OHSS

Secondary Outcome Measures:
  • pregnancy rate [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    the number of pregnancies obtained, wich still is the most important issue for the patients

Estimated Enrollment: 120
Study Start Date: November 2011
Estimated Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: hCG
Active Comparator: hCG and GnRH agonist Drug: Decapeptyl / Gonapeptyl Daily
Decapeptyl 0.2 mg SC once 1day


Ages Eligible for Study:   up to 38 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ICSI patients below 38 years
  • 1,2 or 3 rd IVF-cycle

Exclusion Criteria:

  • PCOS patients
  • patients with endocrinological diseases or problems
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01607203

Contact: Wim Decleer, gynacologist 0032 9 3259220
Contact: Paul Devroey, professor 0032 9 2248070

A Z Jan Palfijn Recruiting
Gent, Oost-vlaanderen, Belgium, 9000
Contact: Wim Decleer, gynacologist    0032 9 2243024   
Contact    0032 9 2248850   
Principal Investigator: Wim Decleer, gynacologist         
Sponsors and Collaborators
AZ Jan Palfijn Gent
Onze Lieve Vrouw Hospital
Principal Investigator: Wim Decleer, gynacologist IVF Centrum Jan Palfijn Gent
  More Information

No publications provided

Responsible Party: Dr. Decleer Wim, gynaecologist, AZ Jan Palfijn Gent Identifier: NCT01607203     History of Changes
Other Study ID Numbers: Dr. Decleer Wim
Study First Received: May 4, 2012
Last Updated: May 24, 2012
Health Authority: Belgium: Ethics Committee

Keywords provided by AZ Jan Palfijn Gent:
mature oocytes
good quality embryo's

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions processed this record on September 18, 2014